Phase II study of 4-demethoxydaunorubicin in patients with adenocarcinoma of the upper gastrointestinal tract.
D000230:Adenocarcinoma / Q000188:drug therapy*; D003630:Daunorubicin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004341:Drug Evaluation; D004938:Esophageal Neoplasms / Q000188:drug therapy*; D006801:Humans; D015255:Idarubicin; D013274:Stomach Neoplasms / Q000188:drug therapy*
D015255:Idarubicin; D003630:Daunorubicin